贝叶斯机器学习模型指导代,个性化抗凝剂剂量决策:ENGAGE AF-TIMI 48试验分析
C Michael Gibson1, Cathy Chen2, Jacqueline Buros-Novik3
1Baim Institute for Clinical Research, Harvard Medical School, Boston, Massachusetts, USA.
JACC. Advances
|February 26, 2026
概括
一个新的贝叶斯式机器学习模型,Adele,通过预测风险并根据个人对中风,出血和死亡的偏好优化edoxaban剂量,为心房患者提供个性化的抗凝药. 与标准方法相比,这种方法可以提高风险预测的准确性.
科学领域:
- 心血管医学 心血管医学
- 医疗保健中的机器学习
- 药物指标 (Pharmacometrics) 是一个指标.
背景情况:
- 目前用于心房的抗凝药使用固定的剂量,忽视患者对中风,出血和死亡等风险的特定偏好.
- 需要个性化治疗策略,以优化心房的抗凝治疗.
研究的目的:
- 开发和评估Adele,这是贝叶斯的机器学习模型,用于在心房患者中个性化,长期的抗凝剂剂量.
- 将患者对中风,出血和死亡风险的偏好纳入剂量决策.
主要方法:
- 开发了Adele,贝叶斯竞争风险,多状态危险模型,训练了来自ENGAGE AF-TIMI 48试验的5380名edoxaban治疗心房的患者.
- 利用患者的药理动力学 (PK) 和基线数据进行个性化,持续的风险预测.
- 将Adele的预测准确度与使用一致性索引的标准Kaplan-Meier估计器进行了比较.
主要成果:
- 阿德尔的预测准确度高于卡普兰-梅尔估计器,改善了对心血管死亡 (+12.1%),残疾 (+11.8%),主要胃肠道出血 (+13.7%) 和缺血性中风 (+3.3%) 的三年预测.
- 该模型显示动态风险预测,调整事件发生后的事件概率,如内出血或缺血性中风.
- 患者示例说明了阿德尔能够根据不同的假设结果偏好确定最佳的edoxaban剂量 (15mg,30mg,60mg).
结论:
- 阿德尔是一个先进的贝叶斯框架,整合了临床因素和PK数据,用于适应性,以患者为中心,偏好加权的预测.
- 该模型通过动态调整预测并指导最佳剂量,使个性化抗凝管理成为可能.
相关概念视频
Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions
54
PK–PD modeling has significantly influenced FDA regulatory decisions, particularly drug approval, dosage optimization, and labeling. These models integrate pharmacokinetics (PK) and pharmacodynamics (PD) to predict drug behavior and effects, aiding in optimizing dosing regimens and enhancing the probability of clinical trial success.One notable example is Nesiritide (Natrecor®), a recombinant human brain natriuretic peptide for treating acute decompensated congestive heart failure...
54
Anticoagulant Drugs: Low-Molecular-Weight Heparins
2.1K
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
2.1K
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
2.6K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
2.6K
Dosage Regimen: Individualization
230
Individualization in dosing regimens is the customization of medication doses for individual patients. Its necessity arises from the goal of maximizing therapeutic benefits while minimizing risks. This approach is pivotal because human responses to drugs can vary widely; what is effective for one person may be inadequate or excessive for another. Interpatient (intersubject) variability refers to differences in drug responses between individuals, while intrapatient (intrasubject) variability...
230
Model-Independent Approaches for Pharmacokinetic Data: Noncompartmental Analysis
379
Noncompartmental analyses offer an alternative method for describing drug pharmacokinetics without relying on a specific compartmental model. In this approach, the drug's pharmacokinetics are assumed to be linear, with the terminal phase log-linear. This assumption allows for simplified analysis and interpretation of the drug's behavior in the body.
One important characteristic of noncompartmental analyses is that drug exposure increases proportionally with increasing doses. This...
One important characteristic of noncompartmental analyses is that drug exposure increases proportionally with increasing doses. This...
379
Drug Dosing in Renal Diseases: Dose Adjustments Based on Drug Clearance and Elimination Rate Constant
279
In patients with renal disease, dosage adjustments are necessary to maintain therapeutic plasma drug concentrations and prevent toxicity or subtherapeutic exposure. Renal impairment alters drug pharmacokinetics, especially in conditions like uremia, where changes such as prolonged elimination half-life and altered apparent volume of distribution can significantly affect drug disposition. These changes require careful modification of the dosing regimen to achieve the desired clinical...
279


